Head-to-head evidence
Tezepelumab (APFS) vs WIN378
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
Tezepelumab (APFS)
Marketed by AstraZeneca
NCT03968978 · Phase 3 · completed
The study randomized 216 participants 1:1 to two active device types but was open-label, with no placebo or blinded control. Its primary endpoint was successful device administration rather than a clinical asthma outcome, and although arm-specific results were posted, the registry does not state whether the between-device comparison was statistically significant.
WIN378
Developed by Windward Bio under a licence from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
NCT05790694 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: July 2027 · NCT07120503 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tezepelumab (APFS)'s landscape · WIN378's landscape